Effect of oral L-arginine on airway hyperresponsiveness to histamine in asthma

H W F M de Gouw, M B Verbruggen, I M Twiss, P J Sterk

Abstract

Background—Nitric oxide (NO) may exert protective properties within the airways of asthmatic patients. It was postulated that airways obstruction in asthma may be associated with endogenous NO deficiency caused by limited availability of NO synthase substrate.

Methods—In a double blind, crossover study 14 asthmatic patients received pretreatment with oral L-arginine (50 mg/kg body weight) or placebo prior to histamine challenge. Histamine challenge was performed until a 50% fall in forced expiratory volume in one second (FEV$_1$) occurred and the response was expressed as the provocative concentration causing a 20% fall in FEV$_1$, (PC$_{20}$) and as the dose-response slope (maximal % fall in FEV$\_1$/cumulative dose (µmol)).

Results—Pretreatment with L-arginine did not affect PC$_{20}$ histamine (mean change in doubling dose 0.18 (95% confidence interval (CI) –0.36 to 0.71), p = 0.5) but the dose-response slope to histamine was slightly reduced (mean change: 0.7 (95% CI 0.6 to 0.9), p = 0.016).

Conclusions—Oral L-arginine does not influence airway hyperresponsiveness to histamine as reflected by PC$_{20}$, although the dose-response slope is slightly reduced in patients with asthma. This indicates only marginal, clinically unimportant limitation of NO synthase substrate in asthma.

(Thorax 1999;54:1033–1035)

Keywords: nitric oxide; asthma; airway hyperresponsiveness

Evidence is accumulating that endogenous nitric oxide (NO) is involved in the pathophysiology of asthma. NO is formed by NO synthase (NOS) using L-arginine as a substrate. It has been shown that the level of NO in exhaled air is increased in subjects with asthma, and that it varies with disease severity. However, the functional role of NO in the pathophysiology of asthma is still unclear.

Recent studies on the modulation of endogenous NO production have revealed protective features of NO during episodes of airways obstruction. Increased airway hyperresponsiveness to non-sensitising stimuli has been observed following inhalation of NOS inhibitors in mildly asthmatic subjects, whereas this could not be found in patients with more severe asthma.

Based on these findings, it can be postulated that airways obstruction in asthma is associated with an endogenous NO deficiency due to limited availability of NOS substrate. We therefore examined the protective effect of oral supplementation of the natural substrate of NOS (L-arginine) on relatively mild and more severe histamine induced airways obstruction in patients with asthma.

Methods

The study subjects comprised 14 non-smoking, atopic, asthmatic patients using inhaled short acting $\beta_2$ agonists on demand only. They had episodic chest symptoms, their baseline forced expiratory volume in one second (FEV$_1$) ranged from 82% to 115% predicted, and all were hyperresponsive to inhaled histamine (provocative concentration causing a fall in FEV$_1$ of 20% (PC$_{20}$) 0.04–6.5 mg/ml). They were asked to refrain from using bronchodilators for at least eight hours before testing.

In a double blind, randomised, crossover study the patients received pretreatment with oral L-arginine or placebo on two separate days separated by an interval of 1–2 weeks. Exhaled NO, FEV$_1$, blood pressure, and heart rate were measured before (baseline) and at 30, 60, and 90 minutes following pretreatment, after which a histamine challenge was performed. Gelatin capsules containing L-arginine (50 mg/kg body weight; Buta, Uitgeest, The Netherlands) or placebo (cellulose) were given 90 minutes before standardised histamine challenges using the two minute tidal breathing method. To examine the effects of L-arginine on mild as well as severe degrees of airways obstruction, the challenge test was continued until a 50% fall in FEV$_1$ from baseline was obtained or when the highest dose was reached. The response was expressed as PC$_{20}$ as a measure of airways sensitivity, whilst the dose-response slope was calculated (maximal % fall in FEV$_1$/maximal dose of histamine (µmol)) as a measure of airways reactivity.

Exhaled NO was measured using a chemiluminescence analyser (Sievers, Boulder, Colo-
Table 1  Effect of pretreatment with placebo or L-arginine on FEV₁, exhaled NO levels, PC₂₀, and dose-response slope to histamine

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>L-arginine</th>
<th>Difference between L-arginine and placebo†</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FEV₁ (% predicted)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>92.8 (85.8 to 99.9)</td>
<td>96.6 (87.9 to 105.4)</td>
<td></td>
</tr>
<tr>
<td>30 min</td>
<td>95.1 (88.3 to 102.0)</td>
<td>95.3 (88.1 to 102.6)</td>
<td>−3.6 (−7.4 to 0.2)</td>
</tr>
<tr>
<td>60 min</td>
<td>95.4 (85.8 to 101.9)</td>
<td>93.3 (85.3 to 101.1)</td>
<td>−3.5 (−8.2 to 0.8)</td>
</tr>
<tr>
<td>90 min</td>
<td>95.2 (87.9 to 102.5)</td>
<td>94.0 (87.2 to 100.8)</td>
<td>−5.0 (−9.3 to −0.8)*</td>
</tr>
<tr>
<td>Exhaled NO (ppb)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>17.4 (12.5 to 22.3)</td>
<td>19.9 (13.0 to 26.8)</td>
<td></td>
</tr>
<tr>
<td>30 min</td>
<td>19.0 (13.9 to 24.2)</td>
<td>21.8 (14.8 to 28.7)</td>
<td>0.3 (−2.3 to 2.8)</td>
</tr>
<tr>
<td>60 min</td>
<td>18.0 (14.0 to 22.0)</td>
<td>21.6 (14.6 to 28.5)</td>
<td>1.1 (−2.9 to 5.1)</td>
</tr>
<tr>
<td>90 min</td>
<td>19.5 (15.5 to 23.5)</td>
<td>22.0 (15.3 to 28.5)</td>
<td>−0.1 (−3.2 to 3.1)</td>
</tr>
<tr>
<td><strong>PC₂₀ histamine (mg/ml)†</strong></td>
<td>0.41 (0.20 to 0.82)</td>
<td>0.46 (0.24 to 0.86)</td>
<td></td>
</tr>
<tr>
<td><strong>DRS (% fall/µmol)†</strong></td>
<td>10.8 (4.8 to 24.5)</td>
<td>7.9 (3.4 to 18.2)*</td>
<td></td>
</tr>
</tbody>
</table>

**FEV₁** = forced expiratory volume in one second; ppb = parts per billion; **PC₂₀** = provocative concentration causing a 20% fall from baseline FEV₁; **DRS** = dose-response slope.

‡Difference in changes from baseline values in FEV₁ and exhaled NO between L-arginine and placebo pretreatment.

Notes:
- FEV₁ = forced expiratory volume in one second; ppb = parts per billion; PC₂₀ = provocative concentration causing a 20% fall from baseline FEV₁; DRS = dose-response slope.
- *p<0.05.
- †Data are geometric mean (95% confidence interval).
- ‡Difference in changes from baseline values in FEV₁ and exhaled NO between L-arginine and placebo pretreatment.

rado, USA) during a vital capacity manoeuvre with a standardised expiratory flow of 0.05 times baseline forced vital capacity per second (0.05 × FVC/s). The subjects inspired “NO-free” air (<2 ppb) during the measurements with their noses clipped. Mean exhaled NO was determined at the plateau and expressed as parts per billion (ppb).

All results were analysed by MANOVA and Student’s paired and unpaired *t* tests. *p* values of <0.05 were considered statistically significant.

The study was approved by the medical ethics committee of the Leiden University Medical Center and all participants gave informed consent.

**Results**

All subjects completed the study. The data are presented in table 1. Baseline FEV₁ and exhaled NO did not differ between the two study days (mean difference 3.8% predicted (95% CI −0.9 to 8.5) and 2.5 ppb (95% CI −2.4 to 7.4), respectively; *p>0.2). There was a slight but significant improvement in FEV₁ following placebo (*p = 0.03) but no significant change in FEV₁ occurred following pretreatment with L-arginine (*p = 0.45; table 1). However, the pre-histamine baseline FEV₁ was not significantly different between the two study days (mean difference −1.3% predicted (95% CI −4.0 to 1.4), *p = 0.3). There was no significant change in exhaled NO levels after L-arginine or placebo (*p>0.1; table 1) nor were blood pressure and heart rate significantly affected (*p>0.4).

Supplementation with L-arginine did not significantly affect airway sensitivity to histamine, determined by PC₂₀ compared with placebo (mean change in doubling dose: 0.18 (95% CI −0.36 to 0.71), *p = 0.5). However, there was a slight but significant reduction in airway reactivity as determined by the dose-response slope following pretreatment with L-arginine compared with placebo (mean change 0.7 (95% CI 0.6 to −0.9), *p = 0.016).

**Discussion**

These results show that oral L-arginine does not affect airway hyperresponsiveness toinhaled histamine in patients with asthma, although a slight reduction in airway reactivity (as indicated by the dose-response slope) was seen. These findings suggest only marginal limitation of NOS substrate in asthmatic subjects in vivo and therefore argue against a clinically relevant deficiency of endogenous NO in asthma.

This is the first study of the effects of L-arginine supplementation on airway hyperresponsiveness in patients with asthma. Previous animal studies have demonstrated the ability of L-arginine to reverse the enhanced bronchoconstriction to non-sensitising stimuli following inhibition of NO synthesis⁵ and to reduce contractility to histamine in vitro.⁶ In addition, they provided indirect evidence for an association between endogenous NO deficiency and the increase in airway sensitivity and reactivity following either respiratory virus infection⁷ or allergen exposure in guinea pigs.⁸ Our results do not confirm these findings, although a slight improvement in airway reactivity occurred following supplementation with oral L-arginine.

It is unlikely that our results can be explained by measurement errors since they were obtained using validated methodology for challenge testing⁹ and measurement of exhaled NO. The dose and timing of L-arginine pretreatment were based on a previous report which showed increased levels in exhaled NO two hours after ingestion of 50 mg/kg L-arginine in asthmatic subjects.⁹ This study, however, we were not able to detect an increase in exhaled NO. Since our patients did not have an L-arginine deficient or weighted diet, we cannot exclude the possibility that these subjects had little or no NOS substrate limitation. Finally, since high concentrations of L-arginine have been shown to act as a non-competitive antagonist of the contractile response to bronchoconstrictor stimuli in vitro,¹⁰ we cannot exclude the contribution of the anti-histamine effects of L-arginine to the present findings.

Besides having immunomodulatory and cytotoxic properties, NO is known to exert protective effects within the airways.² This “relaxant” effect is likely to be derived from constitutive NOS activity (cNOS), of which neuronal NOS (nNOS) in inhibitory non-adrenergic non-cholinergic (iNANC) nerves seems to predominate. It has been suggested that a deficiency of endogenous “relaxant” NO is one of the underlying mechanisms for increased response to bronchoconstrictor stimuli in asthma.¹¹ This may be explained either by a reduction in NOS activity and/or reduced local availability of the NOS substrate. Asthma has been associated with increased exhaled NO levels,¹² of which the major part seems to derive from local inducible NOS (iNOS) activity. The relatively high NO levels produced by iNOS may subsequently attenuate cNOS activity,¹³ thereby potentially reducing its relaxant effects.

Since L-arginine is metabolised not only by NOS, but also by arginase, increased arginase levels and/or activity may limit L-arginine availability. Indeed, both NOS and arginase activity may be increased during inflammation. More importantly, at reduced L-arginine levels, argi-
nase activity is favoured over NO synthesis. However, at present there is no evidence of increased arginase levels and/or activity in asthma. Finally, Chakder and colleagues reported that continuous iNANC activation in smooth muscle strips caused significant decreases in levels of L-arginine. It can be speculated that in asthma the iNANC system may be perpetually activated, thereby exhausting its own bronchodilator features. It remains to be elucidated whether these in vitro findings can be extrapolated to the human situation.

This work was funded by the Netherlands Asthma Foundation (grant 96.10).

Effect of oral l-arginine on airway hyperresponsiveness to histamine in asthma

H W F M de Gouw, M B Verbruggen, I M Twiss and P J Sterk

Thorax 1999 54: 1033-1035
doi: 10.1136/thx.54.11.1033

Updated information and services can be found at:
http://thorax.bmj.com/content/54/11/1033

References

This article cites 11 articles, 3 of which you can access for free at:
http://thorax.bmj.com/content/54/11/1033#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Asthma (1782)
Airway biology (1100)
Lung function (773)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/